Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

SCHERING-PLOUGH PHILS

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Lowering ‘LDL-C’ gets a boost with breakthrough drug

February 19, 2004 - 12:00am

A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. Ezetimibe, launched by Schering-Plough...

Science and Environment